Combivir
Formulated to target HIV replication and indicated to support management of viral load in patients.
Strengths: 300/150mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Antiretroviral
- Pharmacological class
NRTI
- Contraindications
neutropaenia; severe anaemia; hypersensitivity
- Minor side effects
nausea; headache; fatigue; diarrhoea
- Moderate side effects
anaemia; neutropaenia; muscle pain; insomnia
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
ViiV Healthcare
- Onset Time
1–2 weeks
- Duration
Ongoing maintenance
- Storage instructions
Store below 30°C.
- Drug interactions
Zalcitabine; Ribavirin; Stavudine
- Age restrictions
Adjust dose for children by body weight.
Precautions and warnings
monitor liver function; regular blood monitoring for bone marrow suppression; avoid alcohol
Serious side effects
lactic acidosis — requires immediate medical attention; pancreatitis — requires immediate medical attention; peripheral neuropathy — requires immediate medical attention
Patient summary
Formulated to target HIV replication and indicated to support management of viral load in patients.
Mechanism of action
A combination of two nucleoside reverse transcriptase inhibitors that block the reverse transcriptase enzyme, preventing the HIV virus from converting its RNA into DNA, thus inhibiting viral reproduction.
Pregnancy and breastfeeding
Pregnancy: Use if benefit outweighs risk. Breastfeeding: Avoid due to HIV transmission risk.
Combivir
Formulated to target HIV replication and indicated to support management of viral load in patients.
Editorial Notes
- Active ingredient(s): Lamivudine, Zidovudine
- Listed indication(s): HIV Infection
Available option
- 50 tablets - 300/150 mg76-300-150-mg-18259